Key result
L-carnitine treatment (2 g/day) for 1 month significantly improved left ventricular ejection fraction compared to standard therapy alone (4.5% vs. 2.3% improvement, P<0.01).
Why the study?
Does L-carnitine added to standard therapy improve left ventricular ejection fraction and superoxide dismutase activity in patients with ischemic cardiomyopathy?
Population
51 patients with ischemic cardiomyopathy previously treated with angiotensin-converting enzyme inhibitor…
Comparison
L-carnitine 2 g/day added to standard therapy… vs Standard therapy alone for 1 month
Design
RCT, Patients were randomized into two groups
Follow-up
1 month
Authors
Loading...
Supports adjunctive L-carnitine in ischemic cardiomyopathy; extends evidence on SOD activity and LVEF response.
RCT (n=51)
Randomized
Does L-carnitine added to standard therapy improve left ventricular ejection fraction and superoxide dismutase activity in patients with ischemic cardiomyopathy?
Absolute Event Rate: 4.5% vs 2.3%
p-value: p=<0.01
The addition of 2 g/day of L-carnitine to standard pharmacological therapy for 1 month significantly improves left ventricular ejection fraction and increases superoxide dismutase activity in patients with ischemic cardiomyopathy.
Gürlek et al. (2000) conducted an RCT in Ischemic cardiomyopathy (n=51). L-carnitine vs. Standard therapy without L-carnitine was evaluated on Improvement in left ventricular ejection fraction (LVEF) (p=<0.01). L-carnitine treatment (2 g/day) for 1 month significantly improved left ventricular ejection fraction compared to standard therapy alone (4.5% vs. 2.3% improvement, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: